全文获取类型
收费全文 | 63280篇 |
免费 | 6509篇 |
国内免费 | 1436篇 |
专业分类
耳鼻咽喉 | 532篇 |
儿科学 | 1432篇 |
妇产科学 | 1028篇 |
基础医学 | 5570篇 |
口腔科学 | 1929篇 |
临床医学 | 5597篇 |
内科学 | 10065篇 |
皮肤病学 | 803篇 |
神经病学 | 4537篇 |
特种医学 | 1580篇 |
外国民族医学 | 4篇 |
外科学 | 6033篇 |
综合类 | 7122篇 |
现状与发展 | 5篇 |
一般理论 | 3篇 |
预防医学 | 8976篇 |
眼科学 | 773篇 |
药学 | 5402篇 |
29篇 | |
中国医学 | 5078篇 |
肿瘤学 | 4727篇 |
出版年
2024年 | 155篇 |
2023年 | 1305篇 |
2022年 | 2111篇 |
2021年 | 3344篇 |
2020年 | 2837篇 |
2019年 | 3125篇 |
2018年 | 3195篇 |
2017年 | 2573篇 |
2016年 | 2158篇 |
2015年 | 2143篇 |
2014年 | 4491篇 |
2013年 | 4438篇 |
2012年 | 3607篇 |
2011年 | 3874篇 |
2010年 | 3007篇 |
2009年 | 2797篇 |
2008年 | 3063篇 |
2007年 | 3179篇 |
2006年 | 2731篇 |
2005年 | 2291篇 |
2004年 | 1923篇 |
2003年 | 1840篇 |
2002年 | 1354篇 |
2001年 | 1212篇 |
2000年 | 998篇 |
1999年 | 898篇 |
1998年 | 808篇 |
1997年 | 776篇 |
1996年 | 579篇 |
1995年 | 554篇 |
1994年 | 482篇 |
1993年 | 385篇 |
1992年 | 385篇 |
1991年 | 332篇 |
1990年 | 275篇 |
1989年 | 262篇 |
1988年 | 257篇 |
1987年 | 194篇 |
1986年 | 167篇 |
1985年 | 189篇 |
1984年 | 167篇 |
1983年 | 114篇 |
1982年 | 121篇 |
1981年 | 109篇 |
1980年 | 112篇 |
1979年 | 84篇 |
1978年 | 59篇 |
1977年 | 53篇 |
1976年 | 30篇 |
1975年 | 29篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
71.
目的对膝关节前外侧韧带(anterolateral ligament,ALL)的研究进展进行综述,为临床诊治提供参考。方法广泛查阅近年来国内外有关 ALL 损伤诊断及治疗的文献,总结膝关节 ALL 解剖形态、生物力学以及 ALL 损伤机制、治疗现状。结果膝关节 ALL 具有限制胫骨内旋及前移作用,影响膝关节轴移。ALL 损伤后可结合患者体征和 MRI 检查诊断。膝关节 ALL 手术指征尚未统一,但多数学者倾向于对需进行前交叉韧带(anterior cruciate ligament,ACL)重建或翻修且伴有高度轴移试验阳性的患者进行 ALL 重建。目前 ALL 重建方式较多,但尚无最佳治疗术式。此外,由于缺乏高质量的术后长期随访研究,远期临床疗效仍不明确。结论ALL 在维持膝关节稳定性方面具有一定作用,但 ALL 重建技术及临床疗效仍待进一步研究。 相似文献
72.
目的总结应用踇甲皮瓣再造拇指及腓动脉穿支皮瓣游离移植修复足部供区的手术方法及临床效果。方法2016 年 6 月—2018 年 5 月,应用踇甲皮瓣联合腓动脉穿支皮瓣游离移植再造拇指并修复足部供区 15 例。男 10 例,女 5 例;年龄 21~48 岁,平均 34.6 岁。致伤原因:重物压砸伤 7 例,机器绞伤 5 例,电锯切割伤 3 例。Ⅰ度缺损 9 例,Ⅱ度缺损 6 例。入院至皮瓣手术时间 4~7 d,平均 5.2 d。结果术后踇甲皮瓣及腓动脉穿支皮瓣全部成活,切口均Ⅰ期愈合。患者均获随访,随访时间 8~24 个月,平均 16.4 个月。末次随访时,再造拇指指甲生长平整,有光泽,指腹饱满;足部皮瓣外形良好,颜色及质地接近受区。根据中华医学会手外科学会拇手指再造功能评定标准,获优 9 例、良 6 例;根据 Maryland 足功能评分标准,获优 10 例、良 5 例。患者行走步态正常,无跛行及疼痛不适。结论踇甲皮瓣修复拇指Ⅰ、Ⅱ度缺损,再造拇指可获得良好外观及功能;腓动脉穿支皮瓣具有血供可靠、血管恒定、易切取等优点,可有效修复足部供区。 相似文献
73.
《Clinical breast cancer》2020,20(1):80-86
BackgroundEpidermal growth factor receptor (EGFR) is frequently overexpressed in metastatic triple-negative breast cancer (mTNBC). One strategy for overcoming resistance to EGFR inhibition is concomitant inhibition of downstream signaling. The antidiabetic drug metformin inhibits both MAPK and PI3K/mTOR pathway signaling. We evaluated the combination of erlotinib and metformin in a phase 1 study of patients with mTNBC.Patients and MethodsPatients with mTNBC who had received at least one prior line of therapy for metastatic disease were eligible. Erlotinib dose was fixed at 150 mg daily. Metformin dose escalation was planned according to a 3 + 3 design. Dose-limiting toxicities (DLT) were assessed during the first 5 weeks of therapy. The primary objective was to determine the maximum tolerated dose of metformin with fixed-dose erlotinib. Secondary endpoints were response rate, stable disease rate, and progression-free survival.ResultsEight patients were enrolled. The median number of prior therapies for metastatic disease was 2.5 (range, 1-6). No DLT events were reported during the DLT assessment period. Most adverse events were grade 1/2. Grade 3 diarrhea despite maximum supportive care required dose reduction of metformin in one patient. Grade 3 rash led to study withdrawal in one patient. No grade 4 adverse events were reported. The best observed response was stable disease in 2 patients (25%). Median progression-free survival was 60 days (range, 36-61 days).ConclusionErlotinib and metformin were well tolerated in a population of pretreated mTNBC patients but did not demonstrate efficacy in this population. 相似文献
74.
目的对附加钢板技术治疗股骨干髓内钉术后骨不连的历史、现状和进展进行综述。方法广泛查阅国内外关于附加钢板技术治疗股骨干髓内钉术后骨不连的临床研究文献,并进行综合分析。结果自 1997 年附加钢板技术已成功用于治疗股骨干髓内钉术后骨不连,根据原髓内钉是否失效,可分为保留原髓内钉和更换原髓内钉两类。该技术不仅适用于简单骨不连,还可用于合并严重畸形的复杂性骨不连。相比更换髓内钉、更换外侧钢板和双钢板技术,附加钢板技术手术创伤更小,骨折愈合时间更短,骨折愈合率更高,患者能更早重返社会和工作。然而,该技术也存在一些问题有待解决,包括双皮质螺钉固定困难、缺乏适合股骨干解剖型附加钢板以及缺乏术后功能和生活质量的评估研究。结论相比其他翻修固定方式,附加钢板技术能够获得更高的骨折愈合率和更好的临床预后。然而,术后患者能否在功能和生活质量方面进一步获益还有待证实。此外,还需要更高质量的临床对照研究深入证明其是否确实优于其他翻修固定方式。 相似文献
75.
目的探讨重睑术中采用经重睑切口的上睑旋转皮瓣矫正轻、中度内眦赘皮的疗效。方法回顾分析 2016 年 7 月—2017 年 10 月,重睑术中采用经重睑切口的上睑旋转皮瓣矫正轻、中度睑板型内眦赘皮合并单睑的 34 例患者(试验组)临床资料;以同期 38 例接受传统“Z”成形内眦开大术联合重睑术患者为对照(对照组)。两组患者年龄及内侧赘皮分度比较,差异无统计学意义(P>0.05)。于术前及术后 6 d、6 个月测量眼裂长度,计算眼裂长度改善程度;参照内眦赘皮矫正标准评价手术疗效。 结果两组患者切口均Ⅰ期愈合,并获随访 6 个月。两组内眦赘皮明显矫正。试验组内眦处无切口;对照组遗留瘢痕,其中 6 例增生明显。术后 6 d 试验组及对照组眼裂长度改善程度分别为 3.63%±0.07%、3.70%±0.05%;术后 6 个月分别为 4.64%±0.09%、4.46%±0.10%;两组比较差异均无统计学意义(t=0.005,P=0.996;t=0.287,P=0.871)。术后 6 个月疗效评价,试验组优 20 例、良 12 例、差 2 例,优良率 94.12%;对照组优 16 例、良 16 例、差 6 例,优良率 84.21%;差异无统计学意义(χ2=0.796,P=0.372)。 结论经重睑切口的上睑旋转皮瓣矫正轻、中度内眦赘皮手术操作简便、效果满意,内眦处无瘢痕形成。 相似文献
76.
《Surgery for obesity and related diseases》2022,18(6):762-771
BackgroundNew antidiabetic agents (sodium-glucose cotransporter-2 inhibitor [SGLT2i] and glucagon-like peptide-1 receptor agonist [GLP-1RA]) and metabolic surgery have protective effects on metabolic syndromes.ObjectivesTo compare the changes of metabolic parameters and costs among patients with obesity and type 2 diabetes undergoing metabolic surgery and initiating new antidiabetic agents over 12 months.SettingHong Kong Hospital Authority database from 2006–2017.MethodsThis is a population-wide retrospective cohort study consisting of 2616 patients (1810 SGLT2i, 528 GLP-1RA, 278 metabolic surgery). Inverse probability treatment weighting of propensity score was applied to balance baseline covariates of patients with obesity and type 2 diabetes who underwent metabolic surgery, or initiated SGLT2i or GLP-1RA. Metabolic parameters and direct medical costs were measured and compared from baseline to 12 months in metabolic surgery, SGLT2i, and GLP-1RA groups.ResultsPatients in all 3 groups had improved metabolic parameters over a 12-month period. Patients with metabolic surgery achieved significantly better outcomes in BMI (?5.39, ?.56, ?.40 kg/m2, P < .001), % total weight loss (15.16%, 1.34%, 1.63%, P < .001), systolic (?2.21, ?.59, 1.28 mm Hg, P < .001) and diastolic (?1.16, .50, ?.13 mm Hg, P < .001) blood pressure, HbA1c (?1.80%, ?.77%, ?.80%, P < .001), triglycerides (?.64, ?.11, ?.09 mmol/L, P < .001), and estimated glomerular filtration rate (3.08, ?1.37, ?.41 mL/min/1.73m2, P < .001) after 12 months compared with patients with SGLT2i and GLP1-RA. Although the metabolic surgery group incurred the greatest direct medical costs (US$33,551, US$10,945, US$10,627, P < .001), largely due to the surgery itself and related hospitalization, the total monthly direct medical expenditure of metabolic surgery group became lower than that of SGLT2i and GLP-1RA groups at 7 months.ConclusionBeneficial weight loss and metabolic outcomes at 12 months were observed in all 3 groups, among which the metabolic surgery group showed the most remarkable effects but incurred the greatest medical costs. However, studies with a longer follow-up period are warranted to show long-term outcomes. 相似文献
77.
78.
Christopher J. Destache David J. Guervil Keith S. Kaye 《International journal of antimicrobial agents》2019,53(5):644-649
Background
The clinical experience of ceftaroline fosamil (CPT-F) therapy for Gram-positive infective endocarditis is reported from CAPTURE, a retrospective study conducted in the USA.Methods
Data, including patient demographics, medical history, risk factors, microbiological aetiology and clinical outcomes, were collected by review of patient charts between September 2013 and February 2015.Results
Patients (n=55) with Gram-positive endocarditis were treated with CPT-F. The most common risk factors were intravascular devices (43.6%), diabetes mellitus (40.0%) and injection drug use (38.2%). The most commonly isolated pathogens were meticillin-resistant Staphylococcus aureus (MRSA; 80%), meticillin-susceptible S. aureus (MSSA; 7.3%) and coagulase-negative staphylococci (7.3%). CPT-F was given as first-line therapy in 7.3% of patients and as second-line or later therapy in 92.7% of patients, and as monotherapy in 41.8% of patients and as concurrent therapy in 58.2% of patients. Clinical success was observed in 82.6% (19/23) of patients treated with CPT-F as monotherapy. In patients treated with CPT-F as first-line therapy or second-line or later therapy, 75.0% (3/4) and 70.6% (36/51) achieved success, respectively. Clinical success was observed in 77.3% (34/44) of patients with MRSA and 25% (1/4) of patients with MSSA. Two patients discontinued treatment with CPT-F due to an adverse event.Conclusions
CPT-F treatment was associated with a high rate of clinical success in patients with Gram-positive infective endocarditis, including those with risk factors and infections caused by MRSA. A high rate of clinical success was observed in patients treated with CPT-F used as first- line therapy or second-line or later therapy, or as monotherapy or in combination with other antibiotics. 相似文献79.
80.
Christopher N. Cooley Tyler J. Beranek Matthew A. Warpinski Robert Alexander Amanda O. Esquivel 《The American journal of emergency medicine》2019,37(2):199-203